Skip to main
ALC

ALC Stock Forecast & Price Target

ALC Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 18%
Buy 36%
Hold 36%
Sell 9%
Strong Sell 0%

Bulls say

Alcon is a leading global visioncare and surgical company with strong brands, innovative products, and a global reach, making it well-positioned for growth in the global eye care market. The recent spin-off from Novartis offers increased focus and potential for improved profitability as Alcon continues to invest in new products and expands its presence in key markets. The recent launch of new products, such as Dailies Total1 and Centurion, coupled with potential margin improvement, could result in higher-than-expected revenue and EPS growth for the company.

Bears say

Alcon is facing potential challenges in its visioncare and surgical segments, with increased competition and potential share loss to competitors like Johnson & Johnson's PureSee. Despite a strong installed base of surgical equipment, Alcon may struggle to maintain market share without the successful launch of next-gen products like Vivity, which is not expected until 2027. While Alcon has introduced a large stock repurchase authorization and continues to pursue M&A deals, the company's valuation remains a concern with a multiple discount to historical averages and relatively high tariffs impacting earnings. In addition, the recent recall of its IOL product in China may pose a risk to future sales and share recovery.

ALC has been analyzed by 11 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 36% recommend Buy, 36% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alcon Inc. - Registered Shares and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alcon Inc. - Registered Shares (ALC) Forecast

Analysts have given ALC a Buy based on their latest research and market trends.

According to 11 analysts, ALC has a Buy consensus rating as of Aug 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $83.32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $83.32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alcon Inc. - Registered Shares (ALC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.